Last reviewed · How we verify
DWC202310 and DWC202311 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
DWC202310 and DWC202311 (DWC202310 and DWC202311) — Daewoong Pharmaceutical Co. LTD..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DWC202310 and DWC202311 TARGET | DWC202310 and DWC202311 | Daewoong Pharmaceutical Co. LTD. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DWC202310 and DWC202311 CI watch — RSS
- DWC202310 and DWC202311 CI watch — Atom
- DWC202310 and DWC202311 CI watch — JSON
- DWC202310 and DWC202311 alone — RSS
Cite this brief
Drug Landscape (2026). DWC202310 and DWC202311 — Competitive Intelligence Brief. https://druglandscape.com/ci/dwc202310-and-dwc202311. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab